share_log

Invivyd | UPLOAD: Others

Invivyd | UPLOAD: Others

Invivyd | UPLOAD:其他
美股SEC公告 ·  02/23 14:09

Moomoo AI 已提取核心信息

Invivyd, Inc., a biotechnology company, has been informed by the United States Securities and Exchange Commission (SEC) that its Registration Statement on Form S-3, filed on February 9, 2024, will not undergo review by the commission. The SEC's communication, dated February 23, 2024, and addressed to Invivyd's CEO David Hering, explicitly states that the company should not expect a review and reminds them of their responsibility for the accuracy and adequacy of their disclosures. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Invivyd and its management have been directed to contact Lauren Hamill for any further inquiries regarding the matter.
Invivyd, Inc., a biotechnology company, has been informed by the United States Securities and Exchange Commission (SEC) that its Registration Statement on Form S-3, filed on February 9, 2024, will not undergo review by the commission. The SEC's communication, dated February 23, 2024, and addressed to Invivyd's CEO David Hering, explicitly states that the company should not expect a review and reminds them of their responsibility for the accuracy and adequacy of their disclosures. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Invivyd and its management have been directed to contact Lauren Hamill for any further inquiries regarding the matter.
美国证券交易委员会(SEC)已通知生物技术公司Invivyd, Inc.,其于2024年2月9日提交的S-3表格注册声明将不接受该委员会的审查。美国证券交易委员会于2024年2月23日致Invivyd首席执行官戴维·赫林的信函明确指出,该公司不应指望得到审查,并提醒他们对披露的准确性和充分性负责。美国证券交易委员会还引用了与加快注册程序的请求有关的第460和461条。Invivyd及其管理层已被指示联系劳伦·哈米尔,以进一步询问此事。
美国证券交易委员会(SEC)已通知生物技术公司Invivyd, Inc.,其于2024年2月9日提交的S-3表格注册声明将不接受该委员会的审查。美国证券交易委员会于2024年2月23日致Invivyd首席执行官戴维·赫林的信函明确指出,该公司不应指望得到审查,并提醒他们对披露的准确性和充分性负责。美国证券交易委员会还引用了与加快注册程序的请求有关的第460和461条。Invivyd及其管理层已被指示联系劳伦·哈米尔,以进一步询问此事。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息